Our sourcing standards
Every ThinkGLP article follows the same rulebook:
- Authoritative sources only. Medical and regulatory claims trace to FDA prescribing information and labels, peer-reviewed clinical trials (e.g. the STEP, SURMOUNT and SCALE programs), CMS/Medicare.gov, manufacturer documentation, and recognized clinical bodies. Each article lists its sources.
- No invented numbers. Statistics, prices and dates come from a checkable source or they don't appear. Where figures change frequently (drug prices, insurance programs), we say so and point to the official source rather than freezing a number that will go stale.
- Answer-first structure. Articles open with a direct answer, then the detail, because that's how people actually read.
- Education, not advice. No article tells you to start, stop, or change a medication or dose. Every article carries a medical disclaimer.
How content is produced
We research and draft using modern tools, including AI assistance, under a strict editorial rulebook that governs structure, sourcing and the claims above. Fast-changing topics, insurance coverage, Medicare programs, new drug approvals, are verified against current primary sources before publication. Each article shows a "last updated" date, and we revise pages as guidance changes.
How we handle medical/YMYL topics
GLP-1 content sits in a high-trust category because it involves prescription drugs, side effects, weight loss, insurance and medical decisions. ThinkGLP handles that by being transparent about its limits: we are an independent educational publisher, not a clinic, pharmacy, telehealth provider or medical practice. Our owner/editor is not a clinician, and our content is not a substitute for care from a qualified healthcare professional.
Our standard is source-led publishing. Medical and regulatory claims must be tied to checkable sources, high-risk pages must explain limits and warning signs, and we do not publish individualized treatment advice. We maintain a public sources and references page for the main references used across ThinkGLP. If we later use a licensed reviewer, the page will say exactly who reviewed it, their credentials, what they reviewed and when.
Affiliate and commercial policy
ThinkGLP may earn revenue from affiliate links. When a page includes affiliate links, we disclose that relationship near the relevant link or recommendation, not only in the footer. Commercial relationships do not decide our medical conclusions, safety language, ranking order, or whether risks are included.
We keep high-risk medical topics separate from conversion pressure. Pages about pregnancy, breastfeeding, cancer risk, dosing, contraindications, urgent symptoms, eye complications, pancreatitis, kidney injury, or gastroparesis are written for safety and education first. We do not accept partnerships that require exaggerated outcomes, hidden risks, “no prescription needed” claims for prescription drugs, or supplement claims that imply a product is equivalent to Ozempic, Wegovy, Mounjaro or Zepbound.
Claims we refuse to make
Trust is easier to claim than to earn, so we draw hard lines:
- We do not claim our content is "medically reviewed," because we don't employ clinicians. Sites that fake this are common; we'd rather be honest.
- We do not attribute content to invented doctors or credentials.
- We do not guarantee results, promise weight-loss outcomes, or present trial averages as personal predictions.
- We do not accept payment for favorable coverage. Affiliate links, where present, are disclosed and never shape conclusions.
Corrections
When we get something wrong, we fix it and update the article's date. If you spot an error, factual, numerical, or a broken source, please tell us. Corrections are prioritized over new content.
The standing disclaimer
All ThinkGLP content is general education, not medical advice. GLP-1 medications are prescription drugs with real risks and contraindications. Always consult a qualified healthcare professional about your own situation.